Inactivating mutations of CDKN2A and TP53 occur in 90% and 75% of pancreatic cancers, respectively.[60, 90, 91, 92] KRAS mutation can occur in multiple variations of the codon 12, with G12C being the most common. This evidence concerns the gene TP53 and pancreatic neoplasm.